Elevance Health (ELV)
NYSEHealth CareHealthcare PlansSnapshot 2026-07-07
$418.86+2.62%
Close 2026-07-07 · 1-day change
Reading ELV? This analysis is rebuilt every market day. Get it tracked free. No credit card.
Track ELV free→NYSEHealth CareHealthcare PlansSnapshot 2026-07-07
Reading ELV? This analysis is rebuilt every market day. Get it tracked free. No credit card.
Track ELV free→A long-form read on the 1–3 year hold thesis. Slower and deeper than the daily snapshot — it refreshes only when the evidence moves.
This investment represents a durable compounder with a focus on steady earnings growth. The current thesis state is intact, supported by strong recent financial performance despite mixed signals from management.
The market currently prices ELV as cheap compared to its peers, reflecting a low expectations gap. The valuation has recently fallen, indicating that investors may be cautious but not overly pessimistic.
Fundamentals are likely to remain stable given the strong recent performance and management's consistent guidance on earnings and cash flow. However, there is a moderate risk of missing expectations, especially considering the recent history of deep misses in the industry.
The long-term thesis hinges on the performance of sector bellwethers like UNH, CVS, and CI. Positive earnings from these companies could provide a favorable backdrop, while any negative guidance from them could pose risks for ELV.
Overall, the outlook for ELV remains cautiously optimistic, with key dependencies on sector performance and management execution. Not investment advice.
The most important moves since the prior daily snapshot.
Yes, our read has strengthened. The latest earnings beat and the raised FY 2026 adjusted diluted EPS guidance indicate strong financial health and support growth objectives. There are no significant threats noted that would weaken this outlook.
as of 2026-07-07
Specific, dated things to watch for, each with what would confirm it and what would prove it wrong.
Why it matters: Revenue growth helps us see how well the business is doing. It affects overall performance.
Confirms:Q2 2026 operating revenue grows year over year by more than 10%.
Disproves:Q2 2026 operating revenue grows year over year by less than 5%.
Why it matters: An increase in EPS guidance shows management's confidence in business growth. This can boost investor sentiment.
Confirms:Management raises the FY 2026 adjusted diluted EPS guidance. It is now over $26.75.
Disproves:Management keeps or lowers the FY 2026 adjusted diluted EPS guidance. It is now below $26.75.
Why it matters: Changes in membership affect revenue and profits. Losing Medicaid members can slow growth.
Confirms:Medicaid membership declines by less than 3% year over year.
Disproves:Medicaid membership declines by more than 5% year over year.
Why it matters: A strong earnings beat shows good management and strong operations. This can boost investor confidence.
Confirms:Q2 2026 earnings exceed consensus estimates by more than 5%.
Disproves:Q2 2026 earnings fall short of consensus estimates by more than 5%.
Why it matters: Updates on share buybacks show management's trust in the company's worth and future.
Confirms:Management announces a rise in the share buyback limit to over $5.6 billion.
Disproves:Management stops or cuts the share buyback program.
Why it matters: Ongoing share buybacks signal management's commitment to returning value to shareholders. It can support stock price.
Confirms:Elevance Health announces share repurchases of at least $1 billion in Q2 2026.
Disproves:No major share buybacks are announced in Q2 2026.
Why it matters: Strong cash flow is key for funding growth and returning capital to shareholders. It reflects operational health.
Confirms:Operating cash flow for Q2 2026 exceeds $5.5 billion.
Disproves:Operating cash flow for Q2 2026 falls below $5.5 billion.
Why it matters: Operating cash flow is key for funding operations and growth. It shows financial health.
Confirms:Management confirms FY 2026 cash flow guidance of at least $5.5 billion.
Disproves:Management lowers FY 2026 cash flow guidance to below $5 billion.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.